Importance of Platelet Markers for Demonstrating the Presence of Inflammation in the Different Stages of Chronic Renal Diseases

Mehmet Koroglu 1 * , Nilgul Akalin 2, Hanise Ozkan 3, Ozlem Harmankaya 2
More Detail
1 Medical Park Medical School, Internal Medicine, Turkey
2 Bakirkoy Dr Sadi Konuk Training and Research Hospital, İnternal Medicine and Nephrology, Turkey
3 Bakirkoy Dr Sadi Konuk Training and Research Hospital, Internal Medicine, Turkey
* Corresponding Author
EUR J BASIC MED SCI, Volume 5, Issue 1, pp. 1-9.
Download Full Text (PDF)


There is no consensus about association between platelet markers and atherosclerosis in chronic renal diseases. In our study, we aimed to show the effects of platelet markers, in the patient with different stages of chronic renal diseases. Four groups as control, chronic renal diseases, hemodialysis and peritoneal dialysis groups were included; in the study. Venous blood samples were taken from all of the patients following a 12-hour fasting period and anemia and biochemical parameters were measured. Known as atherosclerotic risk factors the levels of C-reactive protein, HOMA-IR, C-peptide with platelet markers (mean platelet volum, plateletcrit, platelet distribution width) were measured and their’s correlations were evaluated. The values of C-reactive protein, HOMA-IR, C-peptide and mean platelet volum in the patient groups were found higher than in the control grup. The positive correlation was determined the between levels of mean platelet volum with C-reactive protein, HOMA-IR, C-peptide, in the patient groups. Plateletcrit levels of the cases in chronic renal disease group were found to be significantly higher than the cases in other groups. No different was shown to the values of platelet distribution width, between the patients with different stages of chronic renal disease. We found that mean platelet volume was increased in the patients with chronic kidney diseases and they might associated the increased risks of inflammation and atherosclerosis. It is possible to use platelet markers as a biomarker to estimate atherosclerosis risk; in chronic kidney diseases.


Koroglu M, Akalin N, Ozkan H, Harmankaya O. Importance of Platelet Markers for Demonstrating the Presence of Inflammation in the Different Stages of Chronic Renal Diseases. Eur J Basic Med Sci. 2015;5(1):1-9.


  • Allon M. Evidence-based cardiology in hemodialysis patients. Am Soc Nephrol. 2013;24(12):1934–1943.
  • Rosner MH, Ronco C, Okusa MD. The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators. Semin Nephrol. 2012; 32 (1):70–78.
  • Siti HN, Kamisah Y, Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease . Vascul Pharmacol. 2015;71: 40-56.
  • Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004; 15(8):475–478.
  • Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract. 2005; 59:981–982.
  • S. G. Chu, R. C. Becker, P. B. Berger, D. L. Bhatt, J. W. Eikelboom, B. Konkle, E. R.,Mohler, M. P. Reilly, and J. S. Berger.Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010 ; 8(1): 148–156.
  • Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial. 2003; 16(3): 245-56.
  • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(4): 62–69.
  • Atamer A, Alisir Ecder S, Akkuş Z, Kocyigit Y,Atamer Y,İlhan N et al. Relationship between leptin, insulin resis¬tance, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in patients with chronic kidney disease. J Int Med Res, 2008; 36(3): 522–28.
  • Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. The prevalence of insulin resis¬tance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther, 2006; 23(6): 988–98.
  • Hung AM, Ikizler TA: Factors determining insulin resistance in chronic he¬modialysis patients. Contrib Nephrol, 2011; 171: 127–34.
  • Shpakov AO, Granstrem OK., Fiziol Zh Im I M Sechenova. C-peptide physiological effects 2013 ;99(2):196-211.
  • Frostegard J. Immunity, atherosclerosis and cardiovascular disease. BMC Medicine. 2013;11; 117.
  • Anjali B. Saxena, MD. Recent advances in the management of peritoneal dialysis patients. 2015, 1; 7:57.
  • Skubala A, Zywiec J, Zelobowska K, Gumprecht J, Grzeszczak W. Continuous glucose monitoring system in 72-hour glucose profile assessment in patients with end-stage renal disease onmaintenance continuous ambulatory peritoneal dialysis. Med Sci Monit 2010, 16 (2):75-83.
  • Siegel-Axel DI, Gawaz M. Platelets and endothelial cells. Semin Thromb Hemost. 2007 ;33(2):128-35.
  • Badimón L, Vilahur G, Padro T. Lipoproteins, platelets and atherothrombosis.Rev Esp Cardiol. 2009 ;62(10):1161-78.
  • Ju HY, Kim JK, Hur SM, Woo SA, Park KA, Park MY, Choi SJ, Hwang SD. Could mean platelet volume be a promising biomarker of progression of chronic kidney disease? Platelets. 2015;26(2):143-7.
  • Hale Sakallı, Esra Baskın, Umut Selda Bayrakçı, Kaan Savaş Gülleroğlu, Gökhan Moray, Mehmet Haberal. Mean Platelet Volume as a Potential Predictor of Renovascular Thrombosis After Renal Transplant. Experimental and Clinical Transplantation. 2011; 27-31: 11(1).
  • Park MJ, Park PW, Seo YH, Kim KH, Park SH, Jeong JH, et al. The relationship between iron parameters and platelet parameters in women with iron deficiency anemia andthrombocytosis. Platelets. 2013;24(5):348-51.